Petah Tikva-based DreaMed Diabetes has evolved into a cloud-based software program that uses gadget mastering to help medical doctors and healthcare specialists better reveal their sufferers with type 1 diabetes. The company has received a CE mark from the European Union, which means it can start advertising and marketing its product in Europe.
Type 1 diabetes is a continual circumstance wherein the pancreas produces little or no insulin, letting glucose enter cells and offering them energy. When insulin is deficient, sugar builds up inside the bloodstream, inflicting lifestyle-threatening complications.
The situation affects more than 90 million people worldwide, and the worldwide market for diabetes-related merchandise is anticipated to reach $20.7 billion in 2022, an increase of greater than 60 percent over 2017. Despite global efforts, kind one diabetes has no therapy thus far, and its treatment, in most cases, focuses on managing blood sugar levels with doses of insulin.
Whereas patients used to be required to prick their hands to monitor their blood sugar levels through glucose meters, the new era has seen the sprouting of continuous glucose video display units (CGM), whose sensors function round the clock. It can generate around 288 glucose degree readings daily without using a finger-pricking wish.
However, with all the blessings CGMs yield, they also create a new headache for physicians: a flood of formerly unavailable information to study to determine the quality direction of treatment for their patients.
To this end, DreaMed Diabetes’ product, Advisor Pro, uses algorithms, system learning, and vague common sense—a form of good judgment wherein an idea could have a diploma of truth among zero. Zero and 1.0—to collect all the information from the diverse insulin pumps, glucose video display units, and the patient’s food consumption. The software then approaches these statistics and shows insulin plans or modifications to the physicians, simplifying and rushing up their work.
“An era has modified, and so have the techniques to optimize treatment. A decade ago, meters were the simplest manner of measurement. Now, with using CGM and taking more than 288 measurements an afternoon, there may be a ton of information we can mix,” stated DreaMed Diabetes CEO Eran Atlas.
Not all healthcare vendors have the information or time to research the vast quantities of facts available to determine the top-of-the-line insulin treatment for their sufferers, stated Atlas.
Atlas stated, “Our project is to simplify treatment by offering smart, personalized diabetes selection assist answers.”
He said Advisor Pro is the most effective diabetes choice guide solution that has acquired regulatory approval for optimizing insulin therapy based on nonstop glucose monitoring statistics.
Pilot research is done at the Schneider Children’s Medical Center and found that the recommendations made by using Advisor Pro were nearly identical to the changes in insulin therapy.
DreaMed Diabetes is now conducting a multi-center medical study in the US, Europe, and Israel in partnership with Glooko, a pacesetter in cellular and web applications for diabetes, to evaluate Advisor Pro. Atlas stated that the trials’ results are anticipated through the end of 2018, with a view to getting FDA approval soon after.
